Who’s Building Health AI’s Trust Infrastructure?

The accelerating integration of artificial intelligence into clinical workflows has outpaced traditional regulatory mechanisms, creating a critical assurance gap. To bridge this divide, a decentralized network of health AI assurance labs is rapidly emerging, driven by a complex interplay of academic, governmental, and private sector leaders. Understanding who is defining the standards for these important validation infrastructures is paramount for federal regulators crafting future oversight, health system compliance officers working through procurement, and venture capitalists assessing market entry viability and regulatory de-risking.

The Coalition for Health AI (CHAI) and the Quest for Consensus

At the forefront of establishing practical assurance frameworks is the Coalition for Health AI (CHAI), a collaborative powerhouse comprising nearly 3,000 organizations from academic medical centers, industry leaders, and government agencies. CHAI’s core mission is to develop and harmonize best practices for the responsible development, deployment, and evaluation of AI in healthcare. Their work is particularly influential in shaping the operational blueprints for regional assurance labs. CHAI’s approach emphasizes consensus-driven standards, recognizing that a unified front is essential to avoid a fragmented regulatory field. A key partnership underpinning this effort is with the Mitre Corporation, which collaborates with CHAI to develop complete testing frameworks. These frameworks aim to provide a standardized methodology for assessing AI model performance, fairness, transparency, and robustness in real-world clinical settings. The goal is to move beyond mere technical validation to encompass broader ethical and operational considerations, addressing concerns like algorithmic drift and potential biases that can undermine trust and patient safety. The composition of CHAI’s membership is critical. It ensures that the standards being developed are informed by diverse perspectives, from frontline clinicians to AI developers and regulatory experts. This broad representation is intended to foster a set of assurance guidelines that are both technically rigorous and practically implementable, directly influencing what future assurance labs will test and how.

ONC HTI-1: Mandating Transparency and Interoperability

While CHAI focuses on developing the “how” of AI assurance, the Office of the National Coordinator for Health Information Technology (ONC) is defining the “what” through regulatory mandates. The ONC Health Data, Technology, and Interoperability: Certification Program Updates, Algorithm Transparency, and Information Sharing (HTI-1) final rule is a landmark piece of legislation that directly impacts the need for and function of AI assurance labs. A central tenet of HTI-1, particularly relevant to decision support intervention (DSI) transparency, is the requirement for developers of certified health IT to provide detailed information about the AI algorithms embedded within their products. This includes documentation on model development, data sources, performance characteristics, and known limitations. The ONC HTI-1 implementation timeline dictates that these transparency requirements have progressively come into effect, with the DSI criterion becoming effective January 1, 2025, and USCDI v3 becoming the new baseline standard as of January 1, 2026. These dates create an urgent demand for standardized, verifiable methods to assess compliance. ONC HTI-1 final rule text The ONC coordinates closely with organizations like CHAI to ensure that the practical standards developed by such coalitions align with federal transparency metrics. This teamwork is important: CHAI’s assurance frameworks can provide the methodological backbone for demonstrating compliance with ONC’s transparency mandates. For health systems, this means that procurement processes will increasingly demand evidence of AI product validation against these emerging standards, shifting the burden of proof onto developers. For investors, understanding the interplay between ONC mandates and CHAI’s testing protocols is essential for evaluating a company’s regulatory readiness and avoiding future compliance burdens.

The National Academy of Medicine’s Ethical Compass

Beyond technical specifications and transparency mandates, the ethical deployment of AI in healthcare remains a paramount concern. The National Academy of Medicine (NAM) plays a key role in shaping this discourse through its AI Code of Conduct. While not a direct regulatory body, NAM’s influence stems from its convening power and its ability to synthesize expert consensus on complex ethical issues. The NAM AI Code of Conduct steering committee roster comprises leading ethicists, clinicians, policymakers, and technologists, reflecting a broad commitment to principles such as fairness, accountability, and privacy. This code provides a high-level ethical framework that informs the more granular technical standards developed by CHAI and complements the transparency requirements of ONC. Assurance labs are increasingly expected to incorporate assessments of ethical considerations, such as bias detection and mitigation strategies, which are directly informed by NAM’s work. For developers, aligning with the NAM Code of Conduct is not just an ethical imperative but a strategic one. Demonstrating adherence to these principles can enhance market acceptance, build trust with providers and patients, and potentially mitigate future regulatory scrutiny. For venture capitalists, investment in companies that proactively embed ethical AI principles, as guided by NAM, represents a de-risked asset with stronger long-term viability.

The Complex Web of Market Entry and Compliance

The concerted efforts of CHAI, ONC, and NAM are coalescing to define a new field for healthcare AI market entry. This emerging infrastructure of localized assurance labs, while still in its nascent stages, promises to standardize the validation process, moving beyond self-attestation to independent verification. For developers, this means a higher bar for market entry. Products will not only require FDA clearance (e.g., 510(k) clearance or De Novo classification for SaMD) but also demonstrable compliance with emerging assurance standards validated through these labs. The FDA has released updated guidance for AI-enabled medical devices, with the August 2025 final Predetermined Change Control Plan (PCCP) guidance now fully in effect, consolidating clearer expectations around transparency, real-world performance monitoring, and PCCPs. This will necessitate strong quality management systems (QMS), adherence to Good Machine Learning Practice (GMLP) principles, and proactive engagement with real-world evidence (RWE) generation to monitor for algorithmic drift and maintain performance. The cost and time associated with these rigorous validation processes will become a significant factor in product development lifecycles and investor expectations. For health system compliance officers, these labs will offer a critical third-party validation mechanism, simplifying due diligence for AI procurement. Instead of relying solely on vendor claims, compliance teams can look for certifications or reports from accredited assurance labs, which will become a de facto requirement for integrating AI into clinical workflows. This shift will help mitigate risks associated with deploying untested or non-transparent AI, addressing concerns about patient safety and data governance (HIPAA, HITRUST, SOC 2). Venture capitalists must now factor the evolving AI assurance ecosystem into their investment theses. Companies that are building regulatory-ready architectures from inception, anticipating these validation requirements, will have a distinct competitive advantage. Those without a clear strategy for working through this decentralized testing infrastructure may face significant regulatory debt, delayed market access, and increased operational costs. The ability to demonstrate a clear pathway through these assurance labs will become as critical as securing a CPT code or achieving Breakthrough Device Designation.

Conclusion

The establishment of national health artificial intelligence assurance labs is not being driven by a single entity but by a powerful, albeit complex, coalition. CHAI is building the technical frameworks, ONC is mandating transparency requirements, and NAM is providing the ethical bedrock. Together, these organizations are shaping a future where AI in healthcare is not just innovative but also safe, effective, and trustworthy. Understanding their intersecting roles is no longer optional. It is fundamental to working through the evolving regulatory field, making informed investment decisions, and ensuring the responsible integration of AI into clinical practice. ** Methodology and Source Note: This report is based on an analysis of public policy filings, organizational charters, and published frameworks from the Coalition for Health AI (CHAI), the Office of the National Coordinator for Health Information Technology (ONC), and the National Academy of Medicine (NAM). Specific references include CHAI draft assurance standards, the ONC HTI-1 final rule text, and NAM AI Code of Conduct publications. Data points regarding CHAI membership composition and the ONC HTI-1 implementation timeline are derived from publicly available documents from these respective organizations.*